A detailed history of Morgan Stanley transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,006,335 shares of ARQT stock, worth $37.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,006,335
Previous 6,083,072 34.14%
Holding current value
$37.3 Million
Previous $19.6 Million 102.07%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$3.25 - $11.77 $6.75 Million - $24.4 Million
-2,076,737 Reduced 34.14%
4,006,335 $39.7 Million
Q4 2023

Feb 13, 2024

BUY
$1.84 - $4.82 $10.8 Million - $28.3 Million
5,861,032 Added 2639.63%
6,083,072 $19.6 Million
Q3 2023

Nov 15, 2023

SELL
$5.31 - $10.98 $1.4 Million - $2.9 Million
-263,938 Reduced 54.31%
222,040 $1.18 Million
Q2 2023

Aug 14, 2023

BUY
$7.51 - $15.0 $1.11 Million - $2.22 Million
148,324 Added 43.93%
485,978 $4.63 Million
Q1 2023

May 15, 2023

BUY
$10.23 - $17.14 $1.43 Million - $2.39 Million
139,590 Added 70.48%
337,654 $3.71 Million
Q4 2022

Feb 14, 2023

BUY
$13.96 - $20.4 $1.02 Million - $1.49 Million
73,138 Added 58.55%
198,064 $2.93 Million
Q3 2022

Nov 14, 2022

BUY
$17.85 - $26.95 $299,112 - $451,601
16,757 Added 15.49%
124,926 $2.39 Million
Q2 2022

Oct 27, 2022

BUY
$16.33 - $22.2 $175,008 - $237,917
10,717 Added 11.0%
108,169 $2.3 Million
Q2 2022

Aug 15, 2022

BUY
$16.33 - $22.2 $175,008 - $237,917
10,717 Added 11.0%
108,169 $2.3 Million
Q1 2022

Oct 27, 2022

SELL
$14.38 - $22.79 $154,110 - $244,240
-10,717 Reduced 9.91%
97,452 $1.88 Million
Q1 2022

May 13, 2022

BUY
$14.38 - $22.79 $638,946 - $1.01 Million
44,433 Added 83.81%
97,452 $1.88 Million
Q4 2021

Feb 14, 2022

SELL
$14.98 - $25.5 $1.36 Million - $2.31 Million
-90,727 Reduced 63.12%
53,019 $1.1 Million
Q3 2021

Nov 15, 2021

BUY
$19.28 - $27.1 $2.77 Million - $3.9 Million
143,746 New
143,746 $3.43 Million

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $560M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.